SHORT REPORTS
Lithium, manic-depressive illness, and psychological test performance For over 10 years patients responding to treatment at a lithium clinic' have been free from psychiatric symptoms. Little is known about the psychological performance of such patients, but a report,2 using the Minnesota Multiphasic Personality Inventory (MMPI), confirmed that lithium produces a response in depression. Clinical impressions agree that lithium responders are patients with typical manic-depressive illness.3 It is still not known how well patients are when taking lithium.
Patients, methods, and results
The first 20 responders to lithium attending the clinic in 1978 were studied psychologically. They had had an average (± SD) of 9-8 3-86 attacks over an average of 9-6±4-92 years before treatment. Since starting treatment they have had an average of 6-25+3-15 years attack free and an estimated average of 7-82 ± 4-35 attacks per person prevented. The Psychological assessment indicates that these responders to lithium might be obsessional. They may be more scrupulous about complying with their treatment and more likely to respond successfully to it. Perhaps a predisposition to manic-depressive illness is associated with obsessional personalities. Would these patients have eventually become chronic mental hospital residents without lithium treatment ? Their normal psychological profiles (in severely affected manicdepressives) emphasise that they are symptom-free between attacks and warrant special care to keep them well. The number of attacks -and admissions prevented emphasises the importance of treating such patients with lithium and reaffirms that lithium has been effective in them. Few treatments in psychiatry are as successful, particularly when followed up for as many years.
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Comment
Investigating possibly complex plasma concentration response relationships is not easy. Variations in findings between trials may result from differences in the patient groups studied. These are likely to be increased by failure to record drop-outs, mixed or ill-defined diagnostic categories,2-5 outpatients with possible compliance problems,2-4 or small numbers.2-4 We tried to control these sources of error. Twenty-seven out of 65 inpatients with endogenous depression taking a constant dose achieved concentrations outside the range of 80-200 ,ug/l of amitriptyline plus nortriptyline, and 20 of these were above the iange. This allowed us to deterniine the significant clinical disadvantage of high concentrations and the improved response in those developing intermediate concentrations within an optimum therapeutic range. The failure of patients above this range to show further improvement between two and six weeks suggests that high concentrations may inhibit spontaneous remission, which is in line with findings with nortriptyline.1 Our results indicate that adjustment of drug plasma concentrations to within the proposed therapeutic range would significantly improve the efficacy of treatment with amitriptyline in endogenous depression. London, 1975. 4 Ziegler, V E, Clayton, P J, and Biggs, J T, Archives of General Psychiatry, 1977 , 34, 607. 5 Coppen, A, et al, Lancet, 1978 
